Blonanserin: a review of its use in the management of schizophrenia

CNS Drugs
Emma D Deeks, Gillian M Keating

Abstract

Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomized and noncomparative trials. Notably, in two randomized, double-blind trials of 8 weeks' duration, blonanserin was noninferior to haloperidol or risperidone for primary endpoints, although it appeared to be better than haloperidol in improving negative symptoms. Blonanserin is generally well tolerated and appears to have an acceptable profile in terms of bodyweight gain. Potential tolerability benefits of the drug in short-term trials included fewer extrapyramidal symptoms than haloperidol and fewer reports of prolactin level increases or hyperprolactinaemia than risperidone. Nevertheless, extrapyramidal symptoms and hyperprolactinaemia were among the most common adverse reactions associated with blonanserin in noncomparative long-term studies. Further prospective and long-term comparative studies are required in order to definitively position blonanserin with respect to other antipsychotic agents. In the meantime...Continue Reading

References

Apr 3, 2013·European Journal of Clinical Pharmacology·Melvin GeorgeSteven Aibor Dkhar
Apr 27, 2010·Annals of General Psychiatry·Tsutomu Furuse, Kenji Hashimoto
Oct 19, 2010·Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry·Tadashi OgawaHiroshi Seno
Jun 15, 2013·Neuropsychiatric Disease and Treatment·Tomomi TenjinNoboru Yamaguchi
Jun 4, 2014·Indian Journal of Psychiatry·T S Sathyanarayana Rao, Chittaranjan Andrade
Dec 1, 2012·Acta Neuropsychiatrica·Manabu TakakiYosuke Uchitomi
Dec 21, 2013·Expert Opinion on Pharmacotherapy·Naren P Rao, Gary Remington
Dec 7, 2013·Expert Review of Neurotherapeutics·Peter J McKenna, Ann M Mortimer
May 14, 2011·Expert Opinion on Emerging Drugs·Falko Biedermann, W Wolfgang Fleischhacker
Jul 24, 2012·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Yu-Guan WenDe-Wei Shang
Jan 29, 2016·Clinical Neuropharmacology·Yasuhide NagoshiKenji Fukui
Jul 17, 2013·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Sakae TakahashiMakoto Uchiyama
Oct 7, 2010·Psychiatry and Clinical Neurosciences·Hidehiro AndohHideo Matsumoto
Mar 19, 2011·Psychiatry and Clinical Neurosciences·Yoshiteru TakekitaToshihiko Kinoshita
Jan 27, 2012·Human Psychopharmacology·Tomomi TenjinNoboru Yamaguchi
May 17, 2011·Psychiatry and Clinical Neurosciences·Koji KatoHideo Matsumoto
Dec 18, 2014·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Manabu TakakiYosuke Uchitomi
May 20, 2014·Psychiatry and Clinical Neurosciences·Yuriko NinomiyaNoboru Yamaguchi
Jan 28, 2014·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Aran Min, Daeho Kim
Jun 14, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tomoko InoueNoboru Yamaguchi
Dec 17, 2014·Journal of Clinical Psychopharmacology·Yutaka Mizuki, Manabu Takaki
Jan 5, 2017·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Eiji KoseHiroyuki Hayashi
Jul 30, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Young Sup WooWon-Myong Bahk
Dec 14, 2018·Beilstein Journal of Organic Chemistry·Muthumani MuthuRaju Ranjith Kumar
Oct 5, 2017·European Journal of Clinical Pharmacology·De-Wei ShangYu-Guan Wen
Nov 18, 2020·Organic & Biomolecular Chemistry·Matiur RahmanAlakananda Hajra

Citations

Dec 9, 2003·The Journal of Clinical Psychiatry·Samuel J Keith, John M Kane
Dec 19, 2003·The Journal of Clinical Psychiatry·Stephen R Marder
Mar 9, 2004·The Journal of Clinical Psychiatry·American Diabetes AssociationNorth American Association for the Study of Obesity
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiWFSBP Task Force on Treatment Guidelines for Schizophrenia
Oct 4, 2008·Psychiatric Services : a Journal of the American Psychiatric Association·Paul N PfeifferMarcia Valenstein

Related Concepts

PRL
Antipsychotic Effect
Atypical Antipsychotic [EPC]
Assay OF Haloperidol
Schizophrenia
Piperazines
Hyperprolactinemia
Extrapyramidal Sign
Piperidines
Haloperidol

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here